Benefits
Galactomannan fiber: the proposed satiety mechanism
Galactomannan is a viscous soluble fiber, and fiber is proposed to promote fullness, but the human carob studies cited here used gram amounts. Studies giving 5 to 50 g of carob pulp fiber measured ghrelin, glucose and blood fats, not appetite, and a carob snack eaten before a meal reduced hunger. Csat+ is about 20% galactomannan, so a capsule supplies far less. No study has measured appetite in people taking Csat+.
Inositols: a small amount of a studied compound
Csat+ is specified to at least 5% inositols, and Pharmactive's published breakdown is mostly D-pinitol (about 4.7%) with only about 0.35% myo-inositol. A 90-day trial in adults with prediabetes did lower HbA1c and fasting glucose, but it used another company's inositol-standardized carob concentrate at 6.66 g a day, about 1.1 g of inositols, which would take roughly 22 g of Csat+ to match.
α-Amylase inhibition: a laboratory finding
Carob water decoctions inhibit α-amylase and α-glucosidase in test-tube assays, although the strongest inhibition came from leaf and stem-bark preparations rather than the pod material used in supplements. One human study pointed the other way: adding 5 g or 10 g of carob pulp fiber to a 50 g glucose drink raised plasma glucose by 47% and 64% and insulin by about 20-25% versus the glucose drink alone.
Blood lipids: carob fiber trials, not Csat+
Reviews of carob describe lipid lowering by its polyphenols and insoluble fiber through the gut, liver and fat tissue. In two placebo-controlled trials in adults with high cholesterol, carob pulp fiber (15 g a day in foods, or 8 g a day of a polyphenol-rich fiber) lowered LDL cholesterol by about 10% and, from baseline, 22%. Carob syrup and carob concentrate trials found no lipid difference from control groups. Csat+ is untested in people.
Prebiotic fermentation: test-tube evidence
Csat+ is specified to at least 2% oligofructoses, and when it was incubated with human faecal bacteria in an anaerobic laboratory model it shifted microbial composition and raised short-chain fatty acid output compared with a control medium. That work was done in glassware. It did not measure appetite, body weight or any outcome in a person, and no study has shown a microbiome change in people taking Csat+.
Antioxidant activity: animal and laboratory data
Gallic acid is the main phenolic measured in carob pod, and Csat+ is specified to at least 0.1%. In mice fed a high-fat, high-sugar diet, Csat+ raised the expression of antioxidant enzymes and lowered inflammatory markers such as IL-6, TNFα and MCP-1 in liver, muscle, fat and aortic tissue. Those were animal experiments funded by the manufacturer, and oxidative stress markers have not been measured in people taking Csat+.
Standardisation and identity
Csat+ is made to a published specification, with galactomannan, inositols, gallic acid and oligofructoses each assayed, so batches should be more consistent than unstandardised carob powder. The extraction process is covered by patent WO 2019/068466 A1, co-assigned to Pharmactive, the Spanish research council CSIC and the Universidad Autónoma de Madrid. A specification and a patent describe how an ingredient is made, not whether it works.
Mechanism of action
Viscous fiber gastric distension
Galactomannan from carob seed is a viscous soluble fiber. Viscous fibers are proposed to add bulk in the stomach and slow its emptying, which could promote fullness. The carob studies cited here gave grams of fiber, and a capsule of a 20% galactomannan extract carries far less; no study has measured this effect with Csat+.
IPG second-messenger insulin signaling
Inositols such as D-pinitol are proposed to act through inositol phosphoglycan (IPG) messengers involved in insulin signalling. Csat+ supplies mostly D-pinitol, in small amounts, and this pathway has not been measured in people taking Csat+.
α-Amylase enzymatic inhibition
In test-tube assays, carob water decoctions (most strongly from leaf and stem bark) inhibited α-amylase and α-glucosidase, the enzymes that break starch and sugars into absorbable glucose. Slowing them could blunt the rise in blood glucose after a meal, but this has not been shown in the human gut after a dose of Csat+.
Gut, liver and fat-tissue lipid effects
Reviews of carob describe lipid lowering by its polyphenols and insoluble fiber through effects on the gut, liver and fat tissue. The carob fiber trials that lowered LDL cholesterol used 8 to 15 g a day, and no lipid effect has been tested at Csat+ doses.
Clinical trials
Animal experiment, not a human trial. C57BL/6J mice were fed a high-fat, high-sugar diet for 26 weeks with or without Csat+ at 4.8% of the diet by weight. Run by Universidad Autónoma de Madrid physiologists and funded by Pharmactive, which sells the ingredient. (de la Fuente-Fernández et al. 2020, Antioxidants (Basel))
Male C57BL/6J mice with diet-induced metabolic syndrome. No humans were studied.
Csat+ lowered blood glucose, HOMA-IR, insulin, total and LDL cholesterol and IL-6 in the mice, prevented diet-induced hypertension and improved vascular function. Appetite was not measured directly, and results in mice eating the extract at 4.8% of their diet do not show what a capsule does in a person.
Animal experiment, not a human trial. Mice with diet-induced metabolic syndrome had two weeks of calorie reduction, with or without aerobic training, with or without Csat+ at 4.8% of the diet. Carried out with and funded by the manufacturer. (de la Fuente-Fernández et al. 2022, Antioxidants (Basel))
Male C57BL/6J mice with diet-induced metabolic syndrome. No humans were studied.
Csat+ added to calorie restriction produced more body-weight loss and less epididymal fat than calorie restriction or exercise alone, and improved insulin sensitivity in liver and skeletal muscle. Appetite was not measured directly, and these mouse results do not establish effects in people.
A 90-day randomized, double-blind, placebo-controlled trial (registered NCT07379931) of a carob liquid concentrate standardized to inositols (15.5% D-pinitol, 165.2 mg/g total inositols), taken as 6.66 g/day in two sachets before lunch and dinner. It was manufactured and funded by Planttech Biotechnology Spain S.L., a different company, and is not standardized to galactomannan, so it is not a trial of Csat+. (Pérez-Piñero et al. 2026, Nutrients)
52 adults with confirmed prediabetes (25 active, 27 placebo), 27 men and 25 women, mean age 45.6 years, mean BMI about 28.
Against placebo, the carob concentrate lowered HbA1c (−0.29% versus −0.04%, p<0.001), fasting glucose, the glucose area under the curve during an oral glucose tolerance test (p=0.015), the insulin area under the curve (p=0.019) and the glucose peak (p=0.034), and improved HOMA-IR (p=0.038) and QUICKI (p=0.024). Fasting insulin fell within the active group but the difference from placebo was not significant (p=0.071). Body weight, BMI and fat mass did not change in either group, and neither did total cholesterol or HDL; LDL differed between groups (p=0.003) because it rose in the placebo group rather than falling on the active product. The product was well tolerated over 90 days with no adverse effects recorded.